420 related articles for article (PubMed ID: 32887484)
1. Airway Inflammation and Host Responses in the Era of CFTR Modulators.
Keown K; Brown R; Doherty DF; Houston C; McKelvey MC; Creane S; Linden D; McAuley DF; Kidney JC; Weldon S; Downey DG; Taggart CC
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887484
[TBL] [Abstract][Full Text] [Related]
2. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.
Harvey C; Weldon S; Elborn S; Downey DG; Taggart C
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408875
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.
Rehman T; Karp PH; Tan P; Goodell BJ; Pezzulo AA; Thurman AL; Thornell IM; Durfey SL; Duffey ME; Stoltz DA; McKone EF; Singh PK; Welsh MJ
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166230
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
Wang S; Niroula S; Hoffman A; Khorrami M; Khorrami M; Yuan F; Gasser GN; Choi S; Liu B; Li J; Metersky ML; Vincent M; Crum CP; Boucher RC; Karmouty-Quintana H; Huang HJ; Sheshadri A; Dickey BF; Parekh KR; Engelhardt JF; McKeon FD; Xian W
Am J Respir Crit Care Med; 2023 Nov; 208(9):930-943. PubMed ID: 37695863
[No Abstract] [Full Text] [Related]
5. Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches.
Ghigo A; Prono G; Riccardi E; De Rose V
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669352
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
Perrem L; Ratjen F
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
[TBL] [Abstract][Full Text] [Related]
7. Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages.
Gillan JL; Davidson DJ; Gray RD
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303535
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
[TBL] [Abstract][Full Text] [Related]
9. Targeting airway inflammation in cystic fibrosis.
McElvaney OJ; Wade P; Murphy M; Reeves EP; McElvaney NG
Expert Rev Respir Med; 2019 Nov; 13(11):1041-1055. PubMed ID: 31530195
[No Abstract] [Full Text] [Related]
10. Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators.
Ribeiro CMP; Higgs MG; Muhlebach MS; Wolfgang MC; Borgatti M; Lampronti I; Cabrini G
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902441
[TBL] [Abstract][Full Text] [Related]
11. Rapid therapeutic advances in CFTR modulator science.
Clancy JP
Pediatr Pulmonol; 2018 Nov; 53(S3):S4-S11. PubMed ID: 30289627
[TBL] [Abstract][Full Text] [Related]
12. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
Carbone A; Vitullo P; Di Gioia S; Conese M
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
[TBL] [Abstract][Full Text] [Related]
13. IL-17 primes airway epithelial cells lacking functional Cystic Fibrosis Transmembrane conductance Regulator (CFTR) to increase NOD1 responses.
Roussel L; Rousseau S
Biochem Biophys Res Commun; 2010 Jan; 391(1):505-9. PubMed ID: 19931506
[TBL] [Abstract][Full Text] [Related]
14. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis.
Harwood KH; McQuade RM; Jarnicki A; Schneider-Futschik EK
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299226
[TBL] [Abstract][Full Text] [Related]
15. Chronic β2AR stimulation limits CFTR activation in human airway epithelia.
Brewington JJ; Backstrom J; Feldman A; Kramer EL; Moncivaiz JD; Ostmann AJ; Zhu X; Lu LJ; Clancy JP
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467332
[TBL] [Abstract][Full Text] [Related]
16. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
17. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.
Saluzzo F; Riberi L; Messore B; Loré NI; Esposito I; Bignamini E; De Rose V
Cells; 2022 Apr; 11(7):. PubMed ID: 35406809
[TBL] [Abstract][Full Text] [Related]
18. A Novel Co-Culture Model Reveals Enhanced CFTR Rescue in Primary Cystic Fibrosis Airway Epithelial Cultures with Persistent
Cholon DM; Greenwald MA; Higgs MG; Quinney NL; Boyles SE; Meinig SL; Minges JT; Chaubal A; Tarran R; Ribeiro CMP; Wolfgang MC; Gentzsch M
Cells; 2023 Nov; 12(22):. PubMed ID: 37998353
[TBL] [Abstract][Full Text] [Related]
19. Role of inhaled antibiotics in the era of highly effective CFTR modulators.
Elborn JS; Blasi F; Burgel PR; Peckham D
Eur Respir Rev; 2023 Mar; 32(167):. PubMed ID: 36631132
[TBL] [Abstract][Full Text] [Related]
20. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
